NCT01200238

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels. Hsp90 belongs to a class of molecular chaperone proteins known to be critical regulators of cancer cell proliferation and survival. Preclinical laboratory experiments have shown STA-9090, an Hsp90 inhibitor, could inhibit ocular melanoma cell lines. The primary objective of this trial is to obtain evaluations of STA-9090 efficacy to metastatic ocular melanoma.

Detailed description

Patients with metastatic ocular melanoma have a poor prognosis and very limited standard therapeutic options. The recent discoveries of GNAQ and GNA11 mutations leading to MAPK pathway activation and the over-expression of c-Met generate the hypothesis that inhibition of hsp90 client proteins will provide clinical benefit. This study tests the feasibility and efficacy of hsp90 inhibition in patients with metastatic ocular melanoma. Multiple components of the MAPK pathway (B-Raf, C-Raf, cdk4) in addition to c-Met are client proteins of hsp90 and dependent of active hsp90 for stability. Inhibition of hsp90 should lead to decreased expression of these client proteins.

Conditions

• Ocular Melanoma

Interventions

Type	Name	Description
DRUG	STA-9090

Timeline

• Start date: 2010-09-17
• Primary completion: 2014-10-12
• Completion: 2016-11-11
• First posted: 2010-09-13
• Last updated: 2018-10-18
• Results posted: 2018-06-27

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study